Indications -- Lupus/Nephritis Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Lupus/Nephritis

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David Howe who wrote (48)	1/6/2003 10:48:58 AM
From: keokalani'nui	Read Replies (2) of 95

HGSI--LymphoStat-B(TM) -- Enrollment Completed for Phase 1 Clinical Trial for Treatment of Lupus Human Genome Sciences has completed patient enrollment in a Phase 1 clinical trial to evaluate LymphoStat-B (human monoclonal antibody to B- lymphocyte stimulator, BLyS) for use in the treatment of systemic lupus erythematosus.(11) The company is in the process of completing the treatment and follow-up phases of the trial, and plans to have results available during the first half of 2003. The multi-center, dose-escalation study is designed to determine the safety and pharmacology of LymphoStat-B in adult patients who are receiving standard therapies for systemic lupus erythematosus. In the future, LymphoStat-B may also be tested in patients with other autoimmune diseases, such as rheumatoid arthritis, immune thrombocytopenic purpura, and Sjogren's syndrome.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next